Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Peter C. Ruben has a total of 116 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Electrophysiological Phenotyping of hiPSC-Derived Atrial Cardiomyocytes Using Automated Patch-Clamp: A Platform for Studying Atrial Inherited Arrhythmias

    by Verónica Jiménez-Sábado, Hosna Babini, Peter C. Ruben, Eric A. Accili, Thomas W. Claydon, Leif Hove-Madsen, Glen F. Tibbits

    Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) represent a robust platform for modelling inherited cardiac disorders. Comparative analysis of ion channel activity in patient-specific and isogenic control lines provides critical insights into the molecular mechanisms underlying channelopathies and arrhythmias. Atrial-specific hiPSC-CMs (hiPSC-aCMs) exhibit distinct electrophysiological properties governed by unique ion channel expression profiles, underscoring the need for optimized methodologies to record atrial ionic currents accurately. Here, we characterized the electrophysiological features of hiPSC-aCMs using the Nanion Patchliner automated patch-clamp system. An optimized cell dissociation protocol was developed to enhance cell integrity and seal formation, while tailored intra- and extracellular solutions were employed to isolate specific ionic currents. Using this approach, we reliably recorded major atrial currents, including the sodium current (INa), L-type calcium current (ICaL), transient outward potassium current (Ito), ultrarapid component of the delayed rectifier current (IKur), small-conductance calcium-activated potassium current (ISK), and pacemaker funny current (If). The resulting current profiles were reproducible and consistent with those observed in native atrial cardiomyocytes. These findings establish the feasibility of the automated electrophysiological characterization of ion channels in hiPSC-aCMs. This platform enables more efficient investigation of pathogenic variants and facilitates the development of targeted therapeutics for atrial arrhythmias and related channelopathies.


  • Open Access

    SCN3A -related neurodevelopmental disorder: Clinical case reports and biophysical characterization

    by Mohammad-Reza Ghovanloo, Cynthia Gershome, Robin van der Lee, Britt Drogemoller, Linhua Zhang, Allison Matthews, Ingrid Blydt-Hansen, Sarah M. Nikkel, Michelle Demos, Wyeth W. Wasserman, et al.

    SCN3A, the gene encoding the voltage-gated sodium channel, Nav1.3, plays a critical role in early neuronal development. Although traditionally considered a neonatal channel, emerging evidence has linked SCN3A mutations to a spectrum of neurodevelopmental disorders. Here, we report two clinical cases involving rare SCN3A variants: one with a de novo p.L209P mutation and another with compound heterozygous p.N52H and p.E1809K variants. Whole-exome sequencing and clinical phenotyping revealed overlapping features of global developmental delay, hypotonia, structural brain abnormalities, and, in one case, epilepsy and dystonia. To evaluate their functional impact, we expressed each mutant independently in CHO cells co-transfected with β1 subunits and performed whole-cell patch-clamp electrophysiology. p.N52H reduced current density and hyperpolarized activation, suggesting mixed gain- and loss-of-function effects. p.L209P selectively hyperpolarized the activation curve, while p.E1809K altered fast inactivation and accelerated recovery kinetics. These findings demonstrate that SCN3A variants can disrupt excitability through diverse biophysical mechanisms. Our study expands the clinical and functional landscape of SCN3A-related disorders and underscores the importance of variant-level characterization to guide diagnosis and future therapeutic strategies.


  • Open Access

    Structural basis for the rescue of hyperexcitable cells by the amyotrophic lateral sclerosis drug Riluzole

    by David Hollingworth, Frances Thomas, Dana A. Page, Mohamed A. Fouda, Raquel Lopez-Rios De Castro, Altin Sula, Vitaliy B. Mykhaylyk, Geoff Kelly, Martin B. Ulmschneider, Peter C. Ruben, et al.

    Neuronal hyperexcitability is a key element of many neurodegenerative disorders including the motor neuron disease Amyotrophic Lateral Sclerosis (ALS), where it occurs associated with elevated late sodium current (INaL). INaL results from incomplete inactivation of voltage-gated sodium channels (VGSCs) after their opening and shapes physiological membrane excitability. However, dysfunctional increases can cause hyperexcitability-associated diseases. Here we reveal the atypical binding mechanism which explains how the neuroprotective ALS-treatment drug riluzole stabilises VGSCs in their inactivated state to cause the suppression of INaL that leads to reversed cellular overexcitability. Riluzole accumulates in the membrane and enters VGSCs through openings to their membrane-accessible fenestrations. Riluzole binds within these fenestrations to stabilise the inactivated channel state, allowing for the selective allosteric inhibition of INaL without the physical block of Na+ conduction associated with traditional channel pore binding VGSC drugs. We further demonstrate that riluzole can reproduce these effects on a disease variant of the non-neuronal VGSC isoform Nav1.4, where pathologically increased INaL is caused directly by mutation. Overall, we identify a model for VGSC inhibition that produces effects consistent with the inhibitory action of riluzole observed in models of ALS. Our findings will aid future drug design and supports research directed towards riluzole repurposing.


  • Open Access

    Cannabidiol potentiates hyperpolarization-activated cyclic nucleotide–gated (HCN4) channels

    by Dana A. Page, Peter C. Ruben

    Cannabidiol (CBD), the main non-psychotropic phytocannabinoid produced by the Cannabis sativa plant, blocks a variety of cardiac ion channels. We aimed to identify whether CBD regulated the cardiac pacemaker channel or the hyperpolarization-activated cyclic nucleotide–gated channel (HCN4). HCN4 channels are important for the generation of the action potential in the sinoatrial node of the heart and increased heart rate in response to β-adrenergic stimulation. HCN4 channels were expressed in HEK 293T cells, and the effect of CBD application was examined using a whole-cell patch clamp. We found that CBD depolarized the V1/2 of activation in holo-HCN4 channels, with an EC50 of 1.6 µM, without changing the current density. CBD also sped activation kinetics by approximately threefold. CBD potentiation of HCN4 channels occurred via binding to the closed state of the channel. We found that CBD’s mechanism of action was distinct from cAMP, as CBD also potentiated apo-HCN4 channels. The addition of an exogenous PIP2 analog did not alter the ability of CBD to potentiate HCN4 channels, suggesting that CBD also acts using a unique mechanism from the known HCN4 potentiator PIP2. Lastly, to gain insight into CBD’s mechanism of action, computational modeling and targeted mutagenesis were used to predict that CBD binds to a lipid-binding pocket at the C-terminus of the voltage sensor. CBD represents the first FDA-approved drug to potentiate HCN4 channels, and our findings suggest a novel starting point for drug development targeting HCN4 channels.


  • Open Access

    Mechanisms underlying the antiarrhythmic effect of ARumenamide-787 in experimental models of the J wave syndromes and hypothermia

    by José M. Di Diego, Hector Barajas-Martinez, Robert Cox, Victoria M. Robinson, Joseph Jung, Mohamed Fouda, Bence Patocskai, Mena Abdelsayed, Peter C. Ruben, Charles Antzelevitch

    Background: Brugada (BrS) and early repolarization syndromes (ERS), the so-called J wave syndromes (JWS), are associated with life-threatening ventricular arrhythmias. Pharmacologic approaches to therapy are currently limited. In this study, we examine the effects of ARumenamide-787 (AR-787) to suppress the electrocardiographic and arrhythmic manifestations of JWS and hypothermia. Methods: We studied the effects of AR-787 on INa and IKr in HEK-293 cells stably expressing the α- and β1-subunits of the cardiac (NaV1.5) sodium channel and hERG channel, respectively. In addition, we studied its effect on Ito, INa and ICa in dissociated canine ventricular myocytes along with action potentials and ECG from coronary-perfused right (RV) and left (LV) ventricular wedge preparations. The Ito agonist, NS5806 (5–10 μM), ICa blocker, verapamil (2.5 μM), and INa blocker, ajmaline (2.5 μM), were used to mimic the genetic defects associated with JWS and to induce the electrocardiographic and arrhythmic manifestations of JWS (prominent J waves/ST segment elevation, phase 2 reentry and polymorphic VT/VF) in canine ventricular wedge preparations. Results: AR-787 (1, 10 and 50 μM) exerted pleiotropic effects on cardiac ion channels. The predominant effect was inhibition of the transient outward current (Ito) and enhancement of the sodium channel current (INa), with lesser effects to inhibit IKr and augment calcium channel current (ICa). AR-787 diminished the electrocardiographic J wave and prevented and/or suppressed all arrhythmic activity in canine RV and LV experimental models of BrS, ERS and hypothermia. Conclusions: Our findings point to AR-787 as promising candidate for the pharmacologic treatment of JWS and hypothermia.


  • Open Access

    ARumenamides: A novel class of potential antiarrhythmic compounds

    by Mena Abdelsayed, Dana Page, Peter C. Ruben

    Background: Most therapeutics targeting cardiac voltage-gated sodium channels (Nav1.5) attenuate the sodium current (INa) conducted through the pore of the protein. Whereas these drugs may be beneficial for disease states associated with gain-of-function (GoF) in Nav1.5, few attempts have been made to therapeutically treat loss-of-function (LoF) conditions. The primary impediment to designing efficacious therapies for LoF is a tendency for drugs to occlude the Nav1.5 central pore. We hypothesized that molecular candidates with a high affinity for the fenestrations would potentially reduce pore block.Methods and Results: Virtual docking was performed on 21 compounds, selected based on their affinity for the fenestrations in Nav1.5, which included a class of sulfonamides and carboxamides we identify as ARumenamide (AR). Six ARs, AR-051, AR-189, AR-674, AR-802, AR-807 and AR-811, were further docked against Nav1.5 built on NavAb and rNav1.5. Based on the virtual docking results, these particular ARs have a high affinity for Domain III-IV and Domain VI-I fenestrations. Upon functional characterization, a trend was observed in the effects of the six ARs on INa. An inverse correlation was established between the aromaticity of the AR’s functional moieties and compound block. Due to its aromaticity, AR-811 blocked INa the least compared with other aromatic ARs, which also decelerated fast inactivation onset. AR-674, with its aliphatic functional group, significantly suppresses INa and enhances use-dependence in Nav1.5. AR-802 and AR-811, in particular, decelerated fast inactivation kinetics in the most common Brugada Syndrome Type 1 and Long-QT Syndrome Type 3 mutant, E1784K, without affecting peak or persistent INa.Conclusion: Our hypothesis that LoF in Nav1.5 may be therapeutically treated was supported by the discovery of ARs, which appear to preferentially block the fenestrations. ARs with aromatic functional groups as opposed to aliphatic groups efficaciously maintained Nav1.5 availability. We predict that these bulkier side groups may have a higher affinity for the hydrophobic milieu of the fenestrations, remaining there rather than in the central pore of the channel. Future refinements of AR compound structures and additional validation by molecular dynamic simulations and screening against more Brugada variants will further support their potential benefits in treating certain LoF cardiac arrhythmias.


  • Anti‐inflammatory effects of cannabidiol against lipopolysaccharides in cardiac sodium channels

    by Mohamed A. Fouda, Yasmine Fathy Mohamed, Rachel Fernandez, Peter C. Ruben

    Background: Sepsis, caused by a dysregulated response to infections, can lead to cardiac arrhythmias. However, the mechanisms underlying sepsis‐induced inflammation, and how inflammation provokes cardiac arrhythmias, are not well understood. We hypothesized that cannabidiol (CBD) may ameliorate lipopolysaccharide (LPS)‐induced cardiotoxicity, via Toll‐like receptors (TLR4) and cardiac sodium channels (NaV1.5).Methods and results: We incubated human immune cells (THP‐1 macrophages) with LPS for 24 h, then extracted the THP‐1 incubation media. ELISA assays showed that LPS (1 or 5 μg·ml−1), in a concentration‐dependent manner, or MPLA (TLR4 agonist, 5 μg·ml−1) stimulated the THP‐1 cells to release inflammatory cytokines (TNF‐α and IL‐6). Prior incubation (4 h) with CBD (5 μM) or C34 (TLR4 antagonist: 5 μg·ml−1) inhibited LPS and MPLA‐induced release of both IL‐6 and TNF‐α. Human‐induced pluripotent stem cell‐derived cardiomyocytes (hiPSC‐CM) were subsequently incubated for 24 h in the media extracted from THP‐1 cells incubated with LPS, MPLA alone, or in combination with CBD or C34. Voltage‐clamp experiments showed a right shift in the voltage dependence of NaV1.5 activation, steady state fast inactivation (SSFI), increased persistent current and prolonged in silico action potential duration in hiSPC‐CMs incubated in the LPS or MPLA‐THP‐1 media. Co‐incubation with CBD or C34 rescued the biophysical dysfunction caused by LPS and MPLA.Conclusion: Our results suggest that CBD may protect against sepsis‐induced inflammation and subsequent arrhythmias through (i) inhibition of the release of inflammatory cytokines, antioxidant and anti‐apoptotic effects and/or (ii) a direct effect on NaV1.5.


  • Open Access

    Cannabidiol increases gramicidin current in human embryonic kidney cells: An observational study

    by Mohammad-Reza Ghovanloo, Samuel J. Goodchild, Peter C. Ruben

    Gramicidin is a monomeric protein that is thought to non-selectively conduct cationic currents and water. Linear gramicidin is considered an antibiotic. This function is considered to be mediated by the formation of pores within the lipid membrane, thereby killing bacterial cells. The main non-psychoactive active constituent of the cannabis plant, cannabidiol (CBD), has recently gained interest, and is proposed to possess various potential therapeutic properties, including being an antibiotic. We previously determined that CBD’s activity on ion channels could be, in part, mediated by altering membrane biophysical properties, including elasticity. In this study, our goal was to determine the empirical effects of CBD on gramicidin currents in human embryonic kidney (HEK) cells, seeking to infer potential direct compound-protein interactions. Our results indicate that gramicidin, when applied to the extracellular HEK cell membrane, followed by CBD perfusion, increases the gramicidin current.


  • Late sodium current: incomplete inactivation triggers seizures, myotonias, arrhythmias, and pain syndromes

    by Mohamed A. Fouda, Mohammad‐Reza Ghovanloo, Peter C. Ruben

    Acquired and inherited dysfunction in voltage‐gated sodium channels underlies a wide range of diseases. In addition to defects in trafficking and expression, sodium channelopathies are caused by dysfunction in one or several gating properties, for instance activation or inactivation. Disruption of channel inactivation leads to increased late sodium current, which is a common defect in seizure disorders, cardiac arrhythmias skeletal muscle myotonia and pain. An increase in late sodium current leads to repetitive action potentials in neurons and skeletal muscles, and prolonged action potential duration in the heart. In this Topical Review, we compare the effects of late sodium current in brain, heart, skeletal muscle and peripheral nerves. image


  • Open Access

    Cannabidiol increases gramicidin current in human embryonic kidney cells: An observational study

    by Mohammad-Reza Ghovanloo, Samuel J. Goodchild, Peter C. Ruben

    Gramicidin is a monomeric protein that is thought to non-selectively conduct cationic currents and water. Linear gramicidin is considered an antibiotic. This function is considered to be mediated by the formation of pores within the lipid membrane, thereby killing bacterial cells. The main non-psychoactive active constituent of the cannabis plant, cannabidiol (CBD), has recently gained interest, and is proposed to possess various potential therapeutic properties, including being an antibiotic. We previously determined that CBD’s activity on ion channels could be, in part, mediated by altering membrane biophysical properties, including elasticity. In this study, our goal was to determine the empirical effects of CBD on gramicidin currents in human embryonic kidney (HEK) cells, seeking to infer potential direct compound-protein interactions. Our results indicate that gramicidin, when applied to the extracellular HEK cell membrane, followed by CBD perfusion, increases the gramicidin current.